论文部分内容阅读
比较研究了一种新型、窄谱非吸收抗菌剂SMT19969对50株核糖体型艰难梭菌、174株革兰阳性菌、136株革兰阴性肠道厌氧菌和40株革兰阳性好氧菌的体外抑菌活性。SMT19969稀释一倍对艰难梭菌(包括核糖体分型菌株027)的抑菌活性(MIC=0.125~0.5ug/ml,MIC90=0.25ug/ml)强于非达霉素(MIC=0.06~1ug/ml,MIC90=0.5ug/ml);稀释2~6倍的抑菌活性低于万古霉素和甲硝唑。SMT19969和非达霉素对革兰阴性厌氧菌(特别是对脆弱类杆菌)的抑菌活性较万古
A comparative study of a new, narrow-spectrum, non-absorbing antibacterial agent SMT19969 against 50 strains of C. difficile, 174 Gram-positive bacteria, 136 Gram-negative enteric anaerobic bacteria and 40 Gram-positive aerobic bacteria Antibacterial activity in vitro. Antibacterial activity (MIC = 0.125-0.5 ug / ml, MIC90 = 0.25 ug / ml) of C. difficile (including ribosomal strain 027) was more than that of fidagomycin (MIC = 0.06-1ug / ml, MIC90 = 0.5ug / ml); 2 to 6 times diluted antibacterial activity lower than vancomycin and metronidazole. Antibacterial activity of SMT19969 and fidigemycin against Gram-negative anaerobes (especially against Bacteroides fragilis)